Equities research analysts forecast that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will post $5.61 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for Regeneron Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $6.28 and the lowest estimate coming in at $4.60. Regeneron Pharmaceuticals posted earnings per share of $5.23 in the same quarter last year, which would suggest a positive year over year growth rate of 7.3%. The company is expected to announce its next quarterly earnings report on Thursday, February 14th.

According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full-year earnings of $21.49 per share for the current year, with EPS estimates ranging from $20.08 to $22.29. For the next year, analysts anticipate that the firm will report earnings of $22.51 per share, with EPS estimates ranging from $19.08 to $26.69. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, November 6th. The biopharmaceutical company reported $5.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.94 by $0.93. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The company had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same quarter last year, the business earned $3.99 EPS. The business’s revenue was up 10.8% on a year-over-year basis.

REGN has been the subject of several recent analyst reports. Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals to $441.00 and gave the stock a “neutral” rating in a research note on Monday, October 22nd. BidaskClub cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 11th. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $409.00 to $412.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 11th. JPMorgan Chase & Co. set a $405.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, November 7th. Finally, Oppenheimer set a $440.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday. Two research analysts have rated the stock with a sell rating, seventeen have issued a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $408.42.

In other news, Director Joseph L. Goldstein sold 2,000 shares of the stock in a transaction dated Monday, September 24th. The shares were sold at an average price of $388.65, for a total value of $777,300.00. Following the completion of the transaction, the director now owns 13,000 shares in the company, valued at approximately $5,052,450. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 12.42% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Wrapmanager Inc. increased its holdings in Regeneron Pharmaceuticals by 9.9% during the 2nd quarter. Wrapmanager Inc. now owns 1,440 shares of the biopharmaceutical company’s stock valued at $497,000 after acquiring an additional 130 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in Regeneron Pharmaceuticals by 4.7% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 3,144 shares of the biopharmaceutical company’s stock valued at $1,085,000 after acquiring an additional 141 shares in the last quarter. Traynor Capital Management Inc. increased its holdings in Regeneron Pharmaceuticals by 9.8% during the 2nd quarter. Traynor Capital Management Inc. now owns 1,631 shares of the biopharmaceutical company’s stock valued at $572,000 after acquiring an additional 145 shares in the last quarter. Cito Capital Group LLC increased its holdings in Regeneron Pharmaceuticals by 4.3% during the 3rd quarter. Cito Capital Group LLC now owns 3,650 shares of the biopharmaceutical company’s stock valued at $1,475,000 after acquiring an additional 150 shares in the last quarter. Finally, MUFG Securities EMEA plc increased its holdings in Regeneron Pharmaceuticals by 1.7% during the 2nd quarter. MUFG Securities EMEA plc now owns 9,031 shares of the biopharmaceutical company’s stock valued at $3,116,000 after acquiring an additional 152 shares in the last quarter. Institutional investors and hedge funds own 67.24% of the company’s stock.

Shares of REGN stock traded up $8.89 during mid-day trading on Friday, hitting $381.69. The stock had a trading volume of 888,679 shares, compared to its average volume of 835,295. Regeneron Pharmaceuticals has a fifty-two week low of $281.89 and a fifty-two week high of $416.49. The stock has a market capitalization of $40.34 billion, a PE ratio of 28.46, a price-to-earnings-growth ratio of 1.60 and a beta of 1.36. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.30 and a current ratio of 4.04.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: Is it better to buy a fund with a higher or lower NAV?

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.